Bevacizumab

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27275 publications

Use of sacituzumab govitecan in HR+/HER2- metastatic breast cancer following progression on endocrine therapy and chemotherapy: a case report in line with the results of the TROPiCS-02 study.

Use of sacituzumab govitecan in HR+/HER2- metastatic breast cancer following progression on endocrine therapy and chemotherapy: a case report in line with the results of the TROPiCS-02 study.

Journal: Recenti progressi in medicina

Published: September 02, 2026

Systemic inflammatory and nutritional biomarkers associated with anatomical and visual outcomes after intravitreal bevacizumab for diabetic macular oedema.

Systemic inflammatory and nutritional biomarkers associated with anatomical and visual outcomes after intravitreal bevacizumab for diabetic macular oedema.

Journal: Clinical & experimental optometry

Published: September 01, 2026

Comparison of adverse events of three anti-VEGF drugs for the treatment of age-related macular degeneration.

Comparison of adverse events of three anti-VEGF drugs for the treatment of age-related macular degeneration.

Journal: The Malaysian journal of pathology

Published: August 31, 2026

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.

Journal: JAMA oncology

Published: August 27, 2026

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 27, 2026

Initial Impact of Loss of Copay Assistance From a National Nonprofit Fund on Outcomes of Retinal Disease.

Initial Impact of Loss of Copay Assistance From a National Nonprofit Fund on Outcomes of Retinal Disease.

Journal: Journal of vitreoretinal diseases

Published: August 26, 2026

Acute laser-induced maculopathy with secondary exudative neovascular changes.

Acute laser-induced maculopathy with secondary exudative neovascular changes.

Journal: BMJ case reports

Published: August 24, 2026

Ileal Perforation Caused by Pleural Mesothelioma-related Small Intestinal Involvement: A Case Report and Literature Review

Ileal Perforation Caused by Pleural Mesothelioma-related Small Intestinal Involvement: A Case Report and Literature Review

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: August 24, 2026

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.

Journal: Human vaccines & immunotherapeutics

Published: August 22, 2026

Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration.

Cost-neutral adoption of anti-VEGF therapies in neovascular age-related macular degeneration.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: August 21, 2026

Functional and Anatomic Outcomes at 12 Months After Switching to Faricimab in Treatment-Recalcitrant Neovascular Age-Related Macular Degeneration.

Functional and Anatomic Outcomes at 12 Months After Switching to Faricimab in Treatment-Recalcitrant Neovascular Age-Related Macular Degeneration.

Journal: Journal of vitreoretinal diseases

Published: August 20, 2026

Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody-drug conjugate with a topoisomerase inhibitor payload.

Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody-drug conjugate with a topoisomerase inhibitor payload.

Journal: Expert opinion on investigational drugs

Published: August 19, 2026

Showing 1-12 of 27,275

Last Updated: 09/19/2026